Research

Mixed

Senolytic drugs (e.g., Dasatinib + Quercetin) reduce senescent cell burden and improve healthspan parameters in aged, radiation-exposed, and progeroid mice, though clinical use is limited by side effects like neutropenia.

Senolytic drugs like Dasatinib and Quercetin show promise in animal models for improving healthspan and reducing senescent cells. However, human application is currently limited by side effects like blood cell count reduction. This is an emerging field, not yet a standard recommendation for healthy individuals.

ModerateSupportsMEDIUM confidence
Given in combination, D + Q reduce senescent cell burden in aged, radiation-exposed and progeroid mice, while improving health span parameters, including cardiovascular and physical function (Xu et al. 2018)... Trials assessing navitoclax as an anticancer agent report neutropenia and thrombocytopenia (Wilson et al. 2010).
Jodie Birch et al. · Genes & Development · 2020

Why this rating

Evidence is primarily preclinical (murine models); human trials are mentioned but noted to have significant side effects and limited scope.

Source

Senescence and the SASP: many therapeutic avenues

Jodie Birch et al. · Genes & Development · 2020

DOI 10.1101/gad.343129.120

narrative_reviewCited 1,104×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →